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For the purposes of this review, glomerular immune injury is
viewed as a process initiated at the level of glomerular struc-
tures following deposition and interaction of defined immuno-
logic reactants which may activate the synthesis of proinflam-
matory mediators. Renal hemodynamic perturbations and
glomerular capillary wall injury resulting in proteinuria are the
most frequent sequelae. When glomerular injury is initiated by
deposition of antibody with specificity against glomerular anti-
gens (structural or trapped) or against non-renal soluble anti-
gens, the ensuing reaction can be of an inflammatory or
non-inflammatory type. The former is frequently associated
with intraglomerular complement activation, recruitment of
neutrophils and platelets and recruitment or enhanced expres-
sion of sensitized monocytes-macrophages. In noninflamma-
tory forms, capillary wall injury can be mediated by antibody
deposition alone or it may require complement activation.
Regardless the type of injury, activation of a number of prom-
flammatory mediator systems has been documented following
glomerular deposition of immunologic reactants. The metabolic
products formed following activation of these systems may
mediate perturbations in renal hemodynamics and in the per-
meability of the glomerular capillary wall. Moreover, they may
play a regulatory role on the function of endogenous glomerular
or blood borne cells recruited in glomerular structures following
initiation of injury. Table 1 summarizes the mediator systems
which have been studied in various forms of experimental
glomerulonephritis.
The use of powerful investigative tools such as tissue culture
and analytical biochemistry has yielded an impressive amount
of information regarding the biosynthetic capabilities of renal
tissues. The renal glomerulus and its various cell types are now
regarded as active sites of synthesis of lipid compounds with
autacoid and proinflammatory effects. Of the compounds with
proinflammatory effects, major emphasis has been placed on
the biosynthesis and role of eicosanoids. Eicosanoids are oxy-
genated metabolites of arachidonic acid (eicosatetraenoic acid)
and other polyunsaturated fatty acids which contain 20 carbons
(eicosa indicates 20). These polyunsaturated fatty acids are
derived from dietary "essential" fatty acids and are present in
esterified form on membrane phosphoglycerides of most mam-
malian cells. The literature on eicosanoids has been expanding
exponentially with approximately 10 publications now appear-
ing daily, a substantial number of which pertain to the kidney.
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The reader is, therefore, referred to a number of key references
regarding the distribution of arachidonate on renal cell phos-
pholipids [11], the release of arachidonate in response to
cell-surface perturbations or receptor-mediated mechanisms
[121, the renal compartmentalization of enzymes involved in the
sequential conversion of arachidonate to prostaglandins (PG),
thromboxanes (Tx) [131, the metabolites originating via the
cytochrome P450-linked monooxygenase system [14] and the
biosynthesis and proinflammatory role of arachidonate lipoxy-
genation products (hydroxyeicosatetraenoic acids, leukotrienes
and lipoxins) [15, 161. Eicosanoids exhibit a bewildering and
often widely differing spectrum of biological activities with
frequently opposing biological effects which may further de-
pend on the species studied. At the risk of oversimplifying, this
review will regard the renal effects of arachidonate cyclooxy-
genation products (dienoic prostaglandins and thromboxanes)
as being primarily vasoactive while those of arachidonate
lipoxygenation products (hydroxyeicosatetraenoic acids and
leukotrienes) as being mainly proinflammatory. Of additional
relevance to this review is the role of eicosanoids on immuno-
regulation [17] and their potential role in regulating glomerular
cell function, which has primarily been explored in mesangial
cells with respect to their contractile properties [18, 19].
Eicosanoid synthesis and origin in the normal and injured
gomeruIus
The development of accurate, specific and sensitive methods
for the isolation, identification and quantification of eicosanoids
has enabled investigators to assess the synthetic profiles of
these compounds in various renal tissues and segments of the
mammalian nephron as well as their excretory profiles in the
urine. Although considerable variation exists between species,
the normal (non-injured and blood-free) glomerulus studied in
vitro and the glomerular epithelial and mesangial cells studied in
culture spontaneously synthesize primarily prostaglandin PGE2
and PGF2. Production of these eicosanoids is enhanced in the
presence of either substrate (arachidonic acid) or phospholipase
A2 activators such as A23 187 or angiotensin II [201. Under these
conditions, production of thromboxane B2 (TxB2, a stable
immunoreactive metabolite of the active precursor TxA2) and
6-keto-PGF1 (a stable immunoreactive metabolite of prostacy-
dine, PGI2) may also be detectable by radioimmunoassay.
Culture of glomerular endothelial cells has recently become
feasible [21] and should allow profiling of eicosanoids in these
cells as well. In the absence of substrate or phospholipase A2
activators, glomerular synthesis of arachidonate lipoxygenation
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Table 1. Mediator systems in glomerular immune injury
System Reference
Complement (anaphylatoxins, membrane attack 1, 2
complex)
Haggeman factor system 3
Vasoactive amines (histamine, serotonin) 4
Renin-angiotensin system 5, 6
Reactive oxygen radicals 7
Eicosanoids (prostaglandins, thromboxanes, this review
leukotrienes)
Alkyl ether glycerophospholipids (platelet 8, 9
activating factor)
Platelet or leukocyte-derived polycationic 10
molecules
products is usually below the detection limits of the analytical
or quantification method employed (high pressure liquid chro-
matography, radioimmunoassay). Under conditions of phos-
pholipase A2 activation (A23 187), normal rat glomeruli synthe-
size primarily l2-hydroxyeicosatetraenoic acid (HETE) [22]
and, to a lesser extent, leukotriene (LT) B4 [23]. Since no
definitive evidence exists for the presence of arachidonate
lipoxygenases in cultured glomerular endothelial, epithelial or
mesangial cells, inferences can be made that these arachidonate
lipoxygenation products originate from resident glomerular
macrophages.
The interest in directly assessing changes in eicosanoid
synthesis in glomerular injury was prompted by earlier studies
on the effects of non-steroidal anti-inflammatory drugs (inhibi-
tors of arachidonate cyclooxygenation) in various proteinuric
states [24], the protective effects of eicosanoid administration
on murine lupus nephropathy [251, and by observations in
experimental models of ureteral obstruction in which increased
renal synthesis of TxA2 was observed and apparently mediated
renal vasoconstriction [26, 27]. Subsequent studies in various
models of renal injury focused on characterizing changes in the
production of eicosanoids of glomerular or whole kidney origin,
and primarily those exerting vasoactive effects (vasoconstric-
tive: TxA2, PGF2a and vasodilatory: POE2, PGI2). Table 2
summarizes experimental and clinical forms of glomerular
injury in which altered synthesis of these eicosanoids has been
described. The following points merit emphasis with respect to
the immunologically mediated forms of injury: a) Enhanced
thromboxane synthesis is frequently associated with or fol-
lowed by an increased production of other prostaglandins such
as PGE2, PGF2 and PG!2 which exert vasoactive effects
similar to (PGF2,) or opposing (PGE2, PGI2) those of throm-
boxane [28, 29]. b) The cellular source of increased thrombox-
ane synthesis is apparently endogenous glomerular and not
blood-borne although the glomerular cell type has not been
definitively identified [28, 38, 54]. C) Enhanced prostaglandin
and thromboxane synthesis occurs in both inflammatory and
non-inflammatory forms of antibody-mediated glomerular in-
jury [28, 31, 32]. d) The sequence of events leading to increased
glomerular eicosanoid synthesis following antibody deposition
is not known and appears to involve the participation of other
systems such as complement [31]. e) Elimination of systemic
(platelet-derived) thromboxane synthesis using thromboxane
synthase inhibitors may not result in inhibition of glomerular
Table 2. Altered synthesis of arachidonate cyclooxygenation
products in glomerular injury
Glomerular injury model Reference
Immune Anti GBM disease
Murine lupus nephritis
Membranous nephropathy
Immune complex GN
Anti-thymocyte Ab-induced GN
Renal transplant rejection"
SLE nephropathy"
28, 29
30
31, 32
33
34
35, 36
37, 38
Non-immune Minimal change disease"
Diabetic nephropathy
Renal mass ablation
Hypertension
Ureteral obstruction
39
40, 41
42
43, 44
45
Drug or toxin-induced Adriamycin
Glycerol
Endotoxin
Mercuric chloride
ACE inhibitors
Angiotensin II
Cyclosporine A
46
47, 48
49
50
51
52, 19
53
"Indicates studies in which eicosanoids of whole kidney origin were
assessed.
thromboxane [28, 38, 54]. f) In inflammatory forms of immune
injury, the levels of glomerular prostaglandins and thrombo-
xanes generally reflect the stage of inflammation [28, 29].
The ability to measure urinary excretion of eicosanoids in a
reliable and reproducible manner has also allowed important
studies to be performed in the clinical arena, It is generally
accepted that the urinary excretion of POE2 and PGF2r. primar-
ily reflects renal synthesis of these eicosanoids, whereas con-
troversy still exists as to the origin or urinary prostacyclin and
thromboxane. In clinical forms of glomerulonephritis the uri-
nary excretion of eicosanoids has best been studied in female
patients with systemic lupus erythematosus (SLE) with or
without glomerulopathy [37, 381. These studies assessed the
urinary excretion of thromboxane B2 as a marker of renal
thromboxane synthesis and that of 2,3-dinor TxB2, as a marker
of extrarenal thromboxane production (originating primarily
from systemic platelet activation). Moreover, the excretion of
the vasodilators PGE2 and PG!2 (assessed by measuring its
stable immunoreactive metabolite 6-keto-PGF1,) was mea-
sured. Patients with active nephropathy (hypercellularity, infil-
trative changes in interstitial and vascular areas and decreased
glomerular filtration rate) were found to have lower urinary
6-keto-PGF1 and higher TxB2 excretion rates compared to
patients with inactive nephropathy (glomerulosclerosis, inter-
stitial fibrosis). Since the excretion of 2,3-dinor-TxB2 remained
unchanged, it was concluded that the intrarenal synthesis of
TxA2 was specifically altered in these patients. Moreover,
intrarenal platelet activation as a source of increased urinary
TxB2 excretion was regarded to be unlikely, since pharmaco-
logic inhibition of platelet arachidonate cyclooxygenation prod-
ucts or selective platelet-derived thromboxane synthesis was
not associated with reductions in renal urinary TxB2 excretion
in patients with SLE [54].
Studies on the synthesis of arachidonate lipoxygenation
products in glomerular immune injury were prompted by the
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Fig. 1. Time course (14 days) of glomerular eicosanoid synthesis in nephrotoxic serum nephritis induced by a single intravenous injection of a
proteinuric dose of anti-GBM antibody. Enhanced synthesis of HETE and LT occurs in the early heterologous phase (0.5 hr) following induction
of the disease, and is followed by enhanced synthesis of thromboxane A2 (Tx) and other dienoic prostaglandins (PG) at 3 to 8 hours. LT synthesis
subsequently becomes impaired, whereas that of Tx, PG and 12-HETE continues at increased rates over the 14 day period. The hatched horizontal
line indicates eicosanoid synthesis in normal glomeruli. The timing and pattern of glomerular neutrophil (PMN) infiltration (stippled area) and the
onset of proteinuna (dotted diagonal line) are also shown to demonstrate the temporal correlation of these events with eicosanoid synthesis.
demonstration that the normal rat glomerulus can synthesize
12-HETE in response to phospholipase A2 activation [55].
Initial work focused on experimental anti-glomerular basement
membrane (anti-GBM) disease in which glomerular synthesis of
12-HETE was assessed under conditions of phospholipase A2
stimulation. Enhanced conversion of labeled substrate (arachi-
donate) to 12- but not 5-HETE during the heterologous phase of
the disease was demonstrated [56]. When glomerular 12-HETE
synthesis was quantified by radioimmunoassay, the duration of
increased 12-HETE synthesis, was found to be similar to that of
thromboxane A2 (12 to 14 days following induction of the
disease) [28, 56]. Platelets (an abundant source of 12-HETE)
recruited in glomerular capillaries following administration of
anti-GBM Ab were apparently not a major source of glomeruli-
derived 12-HETE, since selective platelet depletion was not
associated with significant reductions in glomerular 12-HETE
levels in platelet depleted rats with anti-GBM disease studied in
parallel with platelet replete controls [56]. In the same disease
model, enhanced glomerular synthesis of 5-HETE and LTB4
was also demonstrated [57]. This phenomenon occurred during
the early heterologous phase of the disease only and it was
short-lived. Moreover, it was dependent on complement depo-
sition and partially dependent on neutrophil infiltration. Inter-
estingly, the initial increase in 5-HETE and LTB4 synthesis (at
15 mm to 24 hr following administration of anti-GBM immuno-
globulin) was followed by an impairment in the capacity of
isolated glomeruli to synthesize these eicosanoids [57]. En-
hanced glomerular leukotriene B4 synthesis has also been
described in non-inflammatory forms of antibody-mediated
glomerular injury, such as passive Heymann nephritis in which
glomerular complement deposition also increases LTB4 syn-
thesis [58] and in cationic immune complex-mediated glomer-
ulonephritis [59]. Figure 1 outlines the temporal changes in
glomerular eicosanoid synthesis in parallel with those in gb-
merular neutrophil infiltration and urinary protein excretion in
experimental anti-GBM disease (nephrotoxic serum nephritis).
A conceptual scheme of the events leading to eicosanoid
synthesis following glomerular deposition and interaction of
immunologic reactants is outlined in Figure 2.
Role of eicosanoids in modulating glomerular immune injury
Three strategies have been employed to assess the potential
role of eicosanoids in modulating glomerular immune injury: a)
exogenous administration of eicosanoids, b) dietary manipula-
tion of polyunsaturated fatty acids, and c) pharmacologic inhi-
bition of endogenous eicosanoid synthesis.
Exogenous administration of the stable prostaglandins PGE1
or PGE2 is associated with improvement in the renal histopa-
thology (hypercellularity, glomerular antibody deposition) and
proteinuria and in the survival of mice (NZB x NZW or MRL/
1 strains) with murine lupus-associated nephritis [25, 63]. Treat-
ment of NZBIW F1 mice with Iloprost, a synthetic prostacy-
dine analog, also had beneficial effects on proteinuria and
survival [64]. Beneficial effects of PGE1 or PGE2 treatment
have also been demonstrated in a murine model of apoferritin-
induced immune complex glomerulonephritis and are associ-
ated with reduced production of anti-apoferritin antibody [65].
Similar effects have been noted following treatment of rats with
anti-GBM disease with the stable compound 15-(S)-15-methyl
PGE1; glomerular hypercellularity and proteinuria were re-
duced [66]. These effects have been attributed to the suppres-
sive role that prostaglandins of the E series have been shown to
exert on mitogenesis and/or function of T cells [17], B cells [67],
natural killer cells [68], and neutrophils [69].
TxA2
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GLOMERULAR IMMUNE INJURY
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Fig. 2, Glomerular immune injury leads to deposition
and interaction of a variety of immune reactants such
as antibody, complement components, cationic proteins
and elicited leukocytes within glomerular structures.
These reactants may directly mediate changes in
eicosanoid synthesis by endogenous glomerular cells.
Eicosanoids may have auto-regulatory effects on
glomerular cells (that is, modulation of mesangial cell
contractility), may mediate intraglomerular vasoactive
effects and giomerular hypertension or may exert
proinflammatory effects and participate in
immunoregulation of immunocompetent glomerular or
blood borne leukocytes.
The rationale for assessing the effect of manipulation of
dietary polyunsaturated fatty acids on glomerular injury is
based on the ability to reduce endogenous synthesis of dienoic
eicosanoids (that is, PGE2, TxA,) by substituting dietary eico-
sapentaenoic acid and other omega-3 polyunsaturated fatty
acids for eicosatetraenoic acid (arachidonic acid). As a conse-
quence, endogenous production of non-dienoic prostaglandins
and thromboxanes predominates. This can be accomplished by
providing fish-based diets which are rich in omega-3 eicosapoly-
enoic acids. Using this approach, beneficial effects have been
described on the renal function and proteinuria in NZB x NZW
F1 and in MRL-l Pr mice with lupus nephritis [70, 71] and in rats
with accelerated nephrotoxic serum nephritis [72]. Suppressive
effects on the immune system (lesser degree of lymphoid
hyperplasia, lower levels of circulating immune complexes) and
prolonged survival were noted [71]. Since the endogenous
production of both PGE2 and TxA2 are reduced as a result of
the eicosapentaenoic acid-rich diets employed in these studies,
it is unclear whether the beneficial effects reported were due to
a reduced TxA2 or an increased PGE3 synthesis. Other studies,
however, contradict these findings. Thus, essential fatty acid
deficiency has been shown to enhance both humoral [73] and
cell-mediated immunity [74]. Furthermore, manipulation of
dietary fatty acids has been shown to exert protective effects
despite a lack of suppression of anti-dsDNA autoantibodies [711
and it can be protective even when initiated following the onset
of nephropathy [75]. A beneficial effect of eicosapentaenoic
acid rich diet on the progression of renal failure has also been
reported in patients with IgA nephropathy [76].
Studies on the effects of pharmacologic manipulation of
eicosanoid synthesis on glomerular immune injury have mainly
focused on the use of inhibitors of arachidonate cyclooxygenase
of thromboxane synthase. In experimental forms of glomerular
immune injury such as anti-GBM disease [28, 29] and cationic
immune complex GN [33] and in many forms of human glomer-
ulonephritis [37, 77, 78], renal cyclooxygenase inhibition using
non-steroidal anti-inflammatory drugs (NSAID) reduces GFR
and RBF. Since an enhanced glomerular synthesis of both the
vasoconstrictor thromboxane and vasodilatory prostaglandins
is found in these forms of GN and because the compromise in
renal hemodynamics induced by NSAID drugs is purported to
result from inhibition of vasodilatory PG synthesis, it can be
proposed that, on a molar basis, the renovascular effect of
vasodilatory prostaglandins following immune injury predomi-
nates over that of thromboxane. Alternatively, inhibition of
vasodilatory PG by NSAID may result in an unopposed effect
of other vasoconstrictors such as angiotensin, the activity of
which could be enhanced in renal immune injury [6]. In certain
forms of glomerular injury such as post-streptococcal glomeru-
lonephritis, decreased urinary excretion of PGE2 and 6-keto-
PGFI,, were reported [79, 80]. Ibuprofen administration to these
patients further reduced urinary excretion of these prostaglan-
dins and this was associated with significant decrements in GFR
and RBF. Interestingly, administration of another nonsteroidal
anti-inflammatory drug, Sulindac, was reported to have no
significant effects on urinary PG excretion or on renal hemody-
namics [801.
The use of selective thromboxane synthase inhibitors in order
to definitively study the vasoactive role of this eicosanoid in
experimental and clinical forms of glomerulonephritis have
A EICOSANOID SYNTHESIS/\
Vasoactive effects and
Glomerular hypertension
Pro-inflammatory,
Immunoregulatory
effects
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produced controversial results. A simple and effective way to
inhibit systemic (primarily platelet-derived) thromboxane pro-
duction in the clinical setting is administration of aspirin in low
doses (75 to 100 mg) [81]. It was realized that in experimental
anti-GBM disease [281, or in patients with lupus nephritis [54],
administration of selective Tx synthase inhibitors or aspirin in
doses sufficient to abolish systemic thromboxane synthesis may
not significantly inhibit glomerular or renal thromboxane syn-
thesis and may not have salutory effects on GFR or RBF [28,
82]. Moreover, the functional significance of enhanced glomer-
ular Tx synthesis appears to depend on the stage of glomerular
injury rather than the actual levels of glomerular Tx. Thus, in
the early heterologous phase of anti-GBM disease (2 to 3 hours)
thromboxane synthase inhibition may ameliorate decrements in
GFR [28]. In later stages (day 14) whole kidney GFR may not be
reduced despite increments in glomerular Tx levels, and the Tx
synthase inhibitor UK 38485 has no effects [29]. Also relevant
are preliminary clinical studies indicating a beneficial short term
effect of a sulfonamide derivative, which selectively antago-
nizes TxA2-induced platelet aggregation and vasoconstriction,
on GFR and RBF of patients with proliferative lupus nephritis
[83].
Studies on the effects of selective thromboxane synthase
inhibition on glomerular permeability to protein have produced
controversial results. In a murine model of adriamycin-induced
glomerulopathy, thromboxane synthase inhibition using
UK38485 significantly reduced glomerular TxB2 synthesis and
proteinuria [46]. Long-term administration of OKY-1581 had no
effects on urinary protein excretion in rats with anti-GBM
disease studied at the autologous phase [29]. In the same
disease model, pretreatment with aspirin was reported to ame-
liorate proteinuria [84]. Two carefully conducted studies as-
sessed the role of thromboxane inhibition on proteinuria follow-
ing induction of glomerulonephritis. In a rat model of unilateral
glomerulonephritis induced by in situ formation of cationic
immune complexes, the Tx synthase inhibit or Dazmegrel did
not ameliorate proteinuria or glomerular hypercellularity 24
hours after induction of glomerular injury despite inhibition of
both glomerular and systemic Tx synthesis [85]. In a variant
model of passive Heymann nephritis, thromboxane synthase
inhibition using OKY-046 significantly reduced proteinuria de-
veloping at early stages of injury (2 hours) independently of
changes in renal hemodynamics [32]. In passive Heymann
nephritis and at later stages of glomerular injury, thromboxane
synthase inhibition using UK38485 had no effect [31]. Of
clinical relevance are the findings of a prospective randomized,
double-blind, placebo controlled study which assessed the role
of platelet inhibitor therapy on the course of Type I membra-
noproliferative glomerulonephritis using combinations of aspi-
rin, 975 mg and dipyridamole, 725 mg daily. Evidence sugges-
tive of slowing of the deterioration of renal function and the
development of end-stage renal disease was reported [861.
Although no eicosanoid measurements were performed in these
studies, it can be assumed that aspirin at the doses employed
inhibited both vasoconstrictor and vasodilatory eicosanoids
[87].
Finally, the availability of arachidonate 5-lipoxygenase inhib-
itors and leukotriene receptor antagonists has allowed investi-
gation of the role of these eicosanoids in mediating hemody-
namic perturbations in glomerular immune injury. Evidence for
such a role was provided in nephrotoxic serum glomerulone-
phritis in which a highly selective LTD4 receptor antagonist
prevented decrements in single nephron GFR by abrogating the
anti-GBM antibody-induced decrements in ultrafiltration coef-
ficient [88].
Concluding remarks
Although an impressive amount of progress has been made in
characterizing the biosynthesis and origin of eicosanoids in
experimental and clinical forms of renal immune injury, much
work needs to be done in order to prove or disprove the
suggestion that these compounds do indeed play a major role in
the pathophysiology or immunobiology of glomerulonephritis.
Most work on characterizing eicosanoid synthesis of glomerular
origin has been based on in vitro observations, and it is
conceivable that under these circumstances changes in eicosa-
noid synthesis may simply be an epiphenomenon of glomerular
cell injury or a marker of glomerular inflammation in a manner
analogous to cardiac enzymes being markers of myocardial
injury. Although thromboxane has been regarded as a potent
vasoconstrictor, particularly upon its original discovery, its
enhanced glomerular synthesis assessed in vitro may not be
associated with decrements in GFR or RBF following induction
of immune injury and the maintenance of these hemodynamic
parameters appears to be critically dependent on an intact
cyclooxygenase system rather than the state of activation of
thromboxane synthase [29, 33, 37, 78]. The available evidence
that prostaglandins and thromboxanes play a role in mediating
changes in the permeability of the glomertilar capillary wall to
protein in a manner independent of changes in hemodynamic
parameters is controversial. Clearly, in experimental forms of
GN, the peak in glomerular elcosanoid synthesis occurs prior to
the onset of significant proteinuria [28, 57, 58]. It can be
hypothesized, therefore, that eicosanoids may play an early
role synergistic to that of other mediator systems (Table 1) that
may become activated following glomerular Ab deposition and
lead to perturbations in capillary wall permeability.
The highly technological in vitro approach to assess the role
of eicosanoids in modulating mesangial cell contractility and
glomerular size has led to attractive hypotheses, particularly
with respect to the ability of thromboxane and leukotrienes to
induce glomerular contraction [18, 191. Yet, some scepticism is
appropriate as to whether eicosanoids do mediate such effects
in vivo and particularly in inflammatory forms of GN in which
the injured glomerulus would be expected to be enlarged as a
result of inflammation rather than contracted as a result of
marked increases in intraglomerular thromboxane and leukotri-
ene levels.
The studies on quantification of glomerular leukotriene syn-
thesis have so far been based on in vitro measurements and
under conditions, such as the presence of phospholipase A2
activators, which allow maximum unmasking of arachidonate
lipoxygenases [56—59]. This approach may overestimate
changes in HETE and LT synthesis occurring solely due to
glomerular deposition of immunologic reactants. Unfortu-
nately, most currently available methods do not reliably detect
glomerular arachidonate lipoxygenation products under unstim-
ulated conditions.
Finally, the role of eicosanoids on intraglomerular immuno-
regulation awaits exploration, particularly in view of the recent
990 Lianos: Glomerular immune injury modulation
discovery of the immunocompetent resident glomerular macro-
phages which could be a source of eicosanoid (HETE, LT)
synthesis and may be of key importance in the pathogenesis of
certain forms of glomerulonephritis [89, 90].
Reprint requests to Dr. Elias A. Lianos, Department of Medicine,
Nephrology Division, Medical College of Wisconsin, Froedtert Memo-
rial Lutheran Hospital, 9200 West Wisconsin Avenue, Milwaukee,
Wisconsin 53226, USA.
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